{
    "abstract": "Background Avian influenza A H9N2 strains have pandemic potential. Methods In this randomized, observer-blind study (ClinicalTrials.gov: NCT01659086), 420 healthy adults, 18\u201364 years of age, received 1 of 10 H9N2 inactivated split-virus vaccination regimens (30 participants per group), or saline placebo (120 participants). H9N2 groups received 2 doses (days 0, 21) of 15 \u00b5g hemagglutinin (HA) without adjuvant, or 1.9 \u00b5g HA + AS03A, 1.9 \u00b5g HA + AS03B, 3.75 \u00b5g HA + AS03A, or 3.75 \u00b5g HA + AS03B; followed by the same H9N2 formulation or placebo (day 182). AS03 is an adjuvant system containing \u03b1-tocopherol (AS03A: 11.86 mg; AS03B: 5.93 mg) and squalene in an oil-in-water emulsion. Immunogenicity (hemagglutination inhibition [HI] and microneutralization assays) and safety were assessed up to day 546. Results All adjuvanted formulations exceeded regulatory immunogenicity criteria at days 21 and 42 (HI assay), with seroprotection and seroconversion rates of \u226594.9% and \u226589.8% at day 21, and 100% and \u226598.1% at day 42. Immunogenicity criteria were also met for unadjuvanted vaccine, with lower geometric mean titers. In groups administered a third vaccine dose (day 182), an anamnestic immune response was elicited with robust increases in HI and microneutralization titers. Injection site pain was reported more frequently with adjuvanted vaccines. No vaccine-related serious adverse events were observed. Conclusions All H9N2 vaccine formulations were immunogenic with a clinically acceptable safety profile; adjuvanted formulations were 4\u20138 times dose-sparing (3.75\u20131.9 vs 15 \u00b5g HA). Trial registration Registered on ClinicalTrials.gov: NCT01659086.",
    "author_highlights": [
        {
            "endOffset": 15770,
            "sentence": "AS03-adjuvanted H9N2 vaccine demonstrated robust immunogenicity in adults.",
            "startOffset": 15696
        },
        {
            "endOffset": 15851,
            "sentence": "A single-dose vaccination strategy may be feasible for adjuvanted H9N2 vaccines.",
            "startOffset": 15771
        },
        {
            "endOffset": 15935,
            "sentence": "The adjuvanted formulations permit an 8-fold antigen dose reduction (1.9 vs 15 \u00b5g).",
            "startOffset": 15852
        },
        {
            "endOffset": 16019,
            "sentence": "An anamnestic immune response was observed after a third dose 182 days post-dose 1.",
            "startOffset": 15936
        },
        {
            "endOffset": 16080,
            "sentence": "All formulations had a clinically acceptable safety profile.",
            "startOffset": 16020
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [],
            "firstpage": "469",
            "issn": "00498114",
            "lastpage": "480",
            "pmid": "22046595",
            "pub_year": 2011,
            "title": "Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.",
            "volume": "86"
        },
        "b0010": {
            "authors": [
                {
                    "first": "J. S.M.",
                    "initial": "J.S.M.",
                    "last": "Peiris"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Guan"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Markwell"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Ghose"
                },
                {
                    "first": "R. G.",
                    "initial": "R.G.",
                    "last": "Webster"
                },
                {
                    "first": "K. F.",
                    "initial": "K.F.",
                    "last": "Shortridge"
                }
            ],
            "doi": "10.1128/JVI.75.20.9679-9686.2001",
            "firstpage": "9679",
            "issn": "0022538X",
            "lastpage": "9686",
            "pmid": "11559800",
            "pub_year": 2001,
            "title": "Cocirculation of avian H9N2 and contemporary \"human\" H3N2 influenza A viruses in pigs in southeastern China: Potential for genetic reassortment?",
            "volume": "75"
        },
        "b0015": {
            "authors": [],
            "firstpage": "418",
            "issn": "00498114",
            "lastpage": "424",
            "pmid": "20949701",
            "pub_year": 2010,
            "title": "Antigenic and genetic characteristics of influenza A(H5N1)and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines.",
            "volume": "85"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Atmar"
                },
                {
                    "first": "Wendy A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "Shital M.",
                    "initial": "S.M.",
                    "last": "Patel"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Katz"
                },
                {
                    "first": "Dewei",
                    "initial": "D.",
                    "last": "She"
                },
                {
                    "first": "Hana",
                    "initial": "H.",
                    "last": "El Sahly"
                },
                {
                    "first": "Justine",
                    "initial": "J.",
                    "last": "Pompey"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Cate"
                },
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Couch"
                }
            ],
            "doi": "10.1086/508174",
            "firstpage": "1135",
            "issn": "10584838",
            "lastpage": "1142",
            "pmid": "17029131",
            "pub_year": 2006,
            "title": "Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations",
            "volume": "43"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Atmar"
                },
                {
                    "first": "Wendy A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Quarles"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Cate"
                },
                {
                    "first": "Shital M.",
                    "initial": "S.M.",
                    "last": "Patel"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Nino"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Wells"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Arden"
                },
                {
                    "first": "Kuo",
                    "initial": "K.",
                    "last": "Guo"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Hill"
                },
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Couch"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.08.044",
            "firstpage": "8066",
            "issn": "0264410X",
            "lastpage": "8072",
            "pmid": "21864622",
            "pub_year": 2011,
            "title": "Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine",
            "volume": "29"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Norbert",
                    "initial": "N.",
                    "last": "Hehme"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Engelmann"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "K\u00fcnzel"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Neumeier"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "S\u00e4nger"
                }
            ],
            "doi": "10.1007/s00430-002-0147-9",
            "firstpage": "203",
            "issn": "03008584",
            "lastpage": "208",
            "pmid": "12458361",
            "pub_year": 2002,
            "title": "Pandemic preparedness: Lessons learnt from H2N2 and H9N2 candidate vaccines",
            "volume": "191"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Ruth A.",
                    "initial": "R.A.",
                    "last": "Karron"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Callahan"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Luke"
                },
                {
                    "first": "Bhagvanji",
                    "initial": "B.",
                    "last": "Thumar"
                },
                {
                    "first": "Josephine",
                    "initial": "J.",
                    "last": "McAuliffe"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Schappell"
                },
                {
                    "first": "Tomy",
                    "initial": "T.",
                    "last": "Joseph"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Coelingh"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Jin"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Kemble"
                },
                {
                    "first": "Brian R.",
                    "initial": "B.R.",
                    "last": "Murphy"
                },
                {
                    "first": "Kanta",
                    "initial": "K.",
                    "last": "Subbarao"
                }
            ],
            "doi": "10.1086/596558",
            "firstpage": "711",
            "issn": "00221899",
            "lastpage": "716",
            "pmid": "19210163",
            "pub_year": 2009,
            "title": "A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults",
            "volume": "199"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Karl G.",
                    "initial": "K.G.",
                    "last": "Nicholson"
                },
                {
                    "first": "Catherine I.",
                    "initial": "C.I.",
                    "last": "Thompson"
                },
                {
                    "first": "Jaco M.",
                    "initial": "J.M.",
                    "last": "Klap"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Wood"
                },
                {
                    "first": "Sally",
                    "initial": "S.",
                    "last": "Batham"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Newman"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Mischler"
                },
                {
                    "first": "Maria C.",
                    "initial": "M.C.",
                    "last": "Zambon"
                },
                {
                    "first": "Iain",
                    "initial": "I.",
                    "last": "Stephenson"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.09.103",
            "firstpage": "171",
            "issn": "0264410X",
            "lastpage": "178",
            "pmid": "19799843",
            "pub_year": 2009,
            "title": "Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations",
            "volume": "28"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Iain",
                    "initial": "I.",
                    "last": "Stephenson"
                },
                {
                    "first": "Karl G.",
                    "initial": "K.G.",
                    "last": "Nicholson"
                },
                {
                    "first": "Reinhardt",
                    "initial": "R.",
                    "last": "Gl\u00fcck"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Mischler"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Newman"
                },
                {
                    "first": "Abraham M.",
                    "initial": "A.M.",
                    "last": "Palache"
                },
                {
                    "first": "Neville Q.",
                    "initial": "N.Q.",
                    "last": "Verlander"
                },
                {
                    "first": "Fiona",
                    "initial": "F.",
                    "last": "Warburton"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Wood"
                },
                {
                    "first": "Maria C.",
                    "initial": "M.C.",
                    "last": "Zambon"
                }
            ],
            "doi": "10.1016/S0140-6736(03)15014-3",
            "firstpage": "1959",
            "issn": "01406736",
            "lastpage": "1966",
            "pub_year": 2003,
            "title": "Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: Phase I randomised trial",
            "volume": "362"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Aichinger"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Grohmann-Izay"
                },
                {
                    "first": "Maikel V.W.",
                    "initial": "M.V.W.",
                    "last": "Van Der Velden"
                },
                {
                    "first": "Sandor",
                    "initial": "S.",
                    "last": "Fritsch"
                },
                {
                    "first": "Manuela",
                    "initial": "M.",
                    "last": "Koska"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Portsmouth"
                },
                {
                    "first": "Mary Kate",
                    "initial": "M.K.",
                    "last": "Hart"
                },
                {
                    "first": "Wael",
                    "initial": "W.",
                    "last": "El-Amin"
                },
                {
                    "first": "Otfried",
                    "initial": "O.",
                    "last": "Kistner"
                },
                {
                    "first": "P. Noel",
                    "initial": "P.N.",
                    "last": "Barrett"
                }
            ],
            "doi": "10.1128/CVI.00275-14",
            "firstpage": "46",
            "issn": "15566811",
            "lastpage": "55",
            "pmid": "25355797",
            "pub_year": 2015,
            "title": "Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted Vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults",
            "volume": "22"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Dormitzer"
                },
                {
                    "first": "Theodore F.",
                    "initial": "T.F.",
                    "last": "Tsai"
                },
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Del Giudice"
                }
            ],
            "doi": "10.4161/hv.8.1.18859",
            "firstpage": "45",
            "issn": "2164554X",
            "lastpage": "58",
            "pub_year": 2012,
            "title": "New technologies for influenza vaccines",
            "volume": "8"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Risi"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Caldwell"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Gilderman"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Berwald"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Fogarty"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Poling"
                },
                {
                    "first": "Dennis",
                    "initial": "D.",
                    "last": "Riff"
                },
                {
                    "first": "Mira",
                    "initial": "M.",
                    "last": "Baron"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Frenette"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Sheldon"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Collins"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Shepard"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Brune"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Ferguson"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Vaughn"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Fries"
                }
            ],
            "doi": "10.1093/infdis/jir172",
            "firstpage": "1729",
            "issn": "00221899",
            "lastpage": "1738",
            "pmid": "21606531",
            "pub_year": 2011,
            "title": "Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: A phase III, placebo-controlled, randomized study",
            "volume": "203"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Suxiang",
                    "initial": "S.",
                    "last": "Tong"
                },
                {
                    "first": "Xueyong",
                    "initial": "X.",
                    "last": "Zhu"
                },
                {
                    "first": "Yan",
                    "initial": "Y.",
                    "last": "Li"
                },
                {
                    "first": "Mang",
                    "initial": "M.",
                    "last": "Shi"
                },
                {
                    "first": "Jing",
                    "initial": "J.",
                    "last": "Zhang"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Bourgeois"
                },
                {
                    "first": "Hua",
                    "initial": "H.",
                    "last": "Yang"
                },
                {
                    "first": "Xianfeng",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Sergio",
                    "initial": "S.",
                    "last": "Recuenco"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Gomez"
                },
                {
                    "first": "Li Mei",
                    "initial": "L.M.",
                    "last": "Chen"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Johnson"
                },
                {
                    "first": "Ying",
                    "initial": "Y.",
                    "last": "Tao"
                },
                {
                    "first": "Cyrille",
                    "initial": "C.",
                    "last": "Dreyfus"
                },
                {
                    "first": "Wenli",
                    "initial": "W.",
                    "last": "Yu"
                },
                {
                    "first": "Ryan",
                    "initial": "R.",
                    "last": "McBride"
                },
                {
                    "first": "Paul J.",
                    "initial": "P.J.",
                    "last": "Carney"
                },
                {
                    "first": "Amy T.",
                    "initial": "A.T.",
                    "last": "Gilbert"
                },
                {
                    "first": "Jessie",
                    "initial": "J.",
                    "last": "Chang"
                },
                {
                    "first": "Zhu",
                    "initial": "Z.",
                    "last": "Guo"
                },
                {
                    "first": "Charles T.",
                    "initial": "C.T.",
                    "last": "Davis"
                },
                {
                    "first": "James C.",
                    "initial": "J.C.",
                    "last": "Paulson"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Stevens"
                },
                {
                    "first": "Charles E.",
                    "initial": "C.E.",
                    "last": "Rupprecht"
                },
                {
                    "first": "Edward C.",
                    "initial": "E.C.",
                    "last": "Holmes"
                },
                {
                    "first": "Ian A.",
                    "initial": "I.A.",
                    "last": "Wilson"
                },
                {
                    "first": "Ruben O.",
                    "initial": "R.O.",
                    "last": "Donis"
                }
            ],
            "doi": "10.1371/journal.ppat.1003657",
            "issn": "15537366",
            "pmid": "24130481",
            "pub_year": 2013,
            "title": "New World Bats Harbor Diverse Influenza A Viruses",
            "volume": "9"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Suxiang",
                    "initial": "S.",
                    "last": "Tong"
                },
                {
                    "first": "Yan",
                    "initial": "Y.",
                    "last": "Li"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Rivailler"
                },
                {
                    "first": "Christina",
                    "initial": "C.",
                    "last": "Conrardy"
                },
                {
                    "first": "Danilo A.",
                    "initial": "D.A.",
                    "last": "Alvarez Castillo"
                },
                {
                    "first": "Li Mei",
                    "initial": "L.M.",
                    "last": "Chen"
                },
                {
                    "first": "Sergio",
                    "initial": "S.",
                    "last": "Recuenco"
                },
                {
                    "first": "James A.",
                    "initial": "J.A.",
                    "last": "Ellison"
                },
                {
                    "first": "Charles T.",
                    "initial": "C.T.",
                    "last": "Davis"
                },
                {
                    "first": "Ian A.",
                    "initial": "I.A.",
                    "last": "York"
                },
                {
                    "first": "Amy S.",
                    "initial": "A.S.",
                    "last": "Turmelle"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Moran"
                },
                {
                    "first": "Shannon",
                    "initial": "S.",
                    "last": "Rogers"
                },
                {
                    "first": "Mang",
                    "initial": "M.",
                    "last": "Shi"
                },
                {
                    "first": "Ying",
                    "initial": "Y.",
                    "last": "Tao"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Weil"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Tang"
                },
                {
                    "first": "Lori A.",
                    "initial": "L.A.",
                    "last": "Rowe"
                },
                {
                    "first": "Scott",
                    "initial": "S.",
                    "last": "Sammons"
                },
                {
                    "first": "Xiyan",
                    "initial": "X.",
                    "last": "Xu"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Frace"
                },
                {
                    "first": "Kim A.",
                    "initial": "K.A.",
                    "last": "Lindblade"
                },
                {
                    "first": "Nancy J.",
                    "initial": "N.J.",
                    "last": "Cox"
                },
                {
                    "first": "Larry J.",
                    "initial": "L.J.",
                    "last": "Anderson"
                },
                {
                    "first": "Charles E.",
                    "initial": "C.E.",
                    "last": "Rupprecht"
                },
                {
                    "first": "Ruben O.",
                    "initial": "R.O.",
                    "last": "Donis"
                }
            ],
            "doi": "10.1073/pnas.1116200109",
            "firstpage": "4269",
            "issn": "00278424",
            "lastpage": "4274",
            "pmid": "22371588",
            "pub_year": 2012,
            "title": "A distinct lineage of influenza A virus from bats",
            "volume": "109"
        },
        "b0075": {
            "authors": [
                {
                    "first": "G. M.",
                    "initial": "G.M.",
                    "last": "Air"
                }
            ],
            "doi": "10.1073/pnas.78.12.7639",
            "firstpage": "7639",
            "issn": "00278424",
            "lastpage": "7643",
            "pmid": "6174976",
            "pub_year": 1981,
            "title": "Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus",
            "volume": "78"
        },
        "b0080": {
            "authors": [
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Nobusawa"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Aoyama"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Kato"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Suzuki"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Tateno"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Nakajima"
                }
            ],
            "doi": "10.1016/0042-6822(91)90588-3",
            "firstpage": "475",
            "issn": "00426822",
            "lastpage": "485",
            "pmid": "2024485",
            "pub_year": 1991,
            "title": "Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses",
            "volume": "182"
        },
        "b0085": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Peiris"
                },
                {
                    "first": "K. Y.",
                    "initial": "K.Y.",
                    "last": "Yuen"
                },
                {
                    "first": "C. W.",
                    "initial": "C.W.",
                    "last": "Leung"
                },
                {
                    "first": "K. H.",
                    "initial": "K.H.",
                    "last": "Chan"
                },
                {
                    "first": "P. L.S.",
                    "initial": "P.L.S.",
                    "last": "Ip"
                },
                {
                    "first": "R. W.M.",
                    "initial": "R.W.M.",
                    "last": "Lai"
                },
                {
                    "first": "W. K.",
                    "initial": "W.K.",
                    "last": "Orr"
                },
                {
                    "first": "K. F.",
                    "initial": "K.F.",
                    "last": "Shortridge"
                }
            ],
            "doi": "10.1016/S0140-6736(99)03311-5",
            "firstpage": "916",
            "issn": "01406736",
            "lastpage": "917",
            "pmid": "10489954",
            "pub_year": 1999,
            "title": "Human infection with influenza H9N2",
            "volume": "354"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Frenette"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Ferguson"
                },
                {
                    "first": "Dennis",
                    "initial": "D.",
                    "last": "Riff"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Sheldon"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Risi"
                },
                {
                    "first": "Casey",
                    "initial": "C.",
                    "last": "Johnson"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Kenney"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Innis"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Fries"
                }
            ],
            "doi": "10.1086/652701",
            "firstpage": "1644",
            "issn": "00221899",
            "lastpage": "1653",
            "pmid": "20423222",
            "pub_year": 2010,
            "title": "Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: A randomized controlled phase 1/2 trial in adults",
            "volume": "201"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Carlos A.",
                    "initial": "C.A.",
                    "last": "DiazGranados"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Dunning"
                },
                {
                    "first": "Murray",
                    "initial": "M.",
                    "last": "Kimmel"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Kirby"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Treanor"
                },
                {
                    "first": "Avi",
                    "initial": "A.",
                    "last": "Collins"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Pollak"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Christoff"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Earl"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Landolfi"
                },
                {
                    "first": "Earl",
                    "initial": "E.",
                    "last": "Martin"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Nathan"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                },
                {
                    "first": "Nadia G.",
                    "initial": "N.G.",
                    "last": "Tornieporth"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                },
                {
                    "first": "H. Keipp",
                    "initial": "H.K.",
                    "last": "Talbot"
                }
            ],
            "doi": "10.1056/NEJMoa1315727",
            "firstpage": "635",
            "issn": "00284793",
            "lastpage": "645",
            "pmid": "25119609",
            "pub_year": 2014,
            "title": "Efficacy of high-dose versus standard-dose influenza vaccine in older adults",
            "volume": "371"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Nolan"
                },
                {
                    "first": "Sumita",
                    "initial": "S.",
                    "last": "Roy-Ghanta"
                },
                {
                    "first": "May",
                    "initial": "M.",
                    "last": "Montellano"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "Rolando",
                    "initial": "R.",
                    "last": "Ulloa-Gutierrez"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Lazcano-Ponce"
                },
                {
                    "first": "Angkool",
                    "initial": "A.",
                    "last": "Kerdpanich"
                },
                {
                    "first": "Marco Aur\u00e9lio Palazzi",
                    "initial": "M.A.P.",
                    "last": "Safadi"
                },
                {
                    "first": "Aurelio",
                    "initial": "A.",
                    "last": "Cruz-Valdez"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Litao"
                },
                {
                    "first": "Fong Seng",
                    "initial": "F.S.",
                    "last": "Lim"
                },
                {
                    "first": "Abiel Mascare\u00f1as",
                    "initial": "A.M.",
                    "last": "De Los Santos"
                },
                {
                    "first": "Miguel Angel Rodriguez",
                    "initial": "M.A.R.",
                    "last": "Weber"
                },
                {
                    "first": "Juan Carlos",
                    "initial": "J.C.",
                    "last": "Tinoco"
                },
                {
                    "first": "Marcela Hernandez De",
                    "initial": "M.H.D.",
                    "last": "Mezerville"
                },
                {
                    "first": "Idis",
                    "initial": "I.",
                    "last": "Faingezicht"
                },
                {
                    "first": "Pensri",
                    "initial": "P.",
                    "last": "Kosuwon"
                },
                {
                    "first": "Pio",
                    "initial": "P.",
                    "last": "Lopez"
                },
                {
                    "first": "Charissa",
                    "initial": "C.",
                    "last": "Borja-Tabora"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Serge",
                    "initial": "S.",
                    "last": "Durviaux"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Fries"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Breuer"
                },
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Innis"
                },
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Vaughn"
                }
            ],
            "doi": "10.1093/infdis/jiu173",
            "firstpage": "545",
            "issn": "00221899",
            "lastpage": "557",
            "pmid": "24652494",
            "pub_year": 2014,
            "title": "Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: Results of a controlled, randomized efficacy trial",
            "volume": "210"
        },
        "b0105": null,
        "b0110": null,
        "b9005": null
    },
    "body_text": [
        {
            "endOffset": 20627,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "A study protocol summary is available at www.gsk-clinicalstudyregister.com (Study ID 116358).",
            "startOffset": 20534,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32770,
            "parents": [],
            "secId": "s0075",
            "sentence": "CBER and CHMP immunogenicity criteria were met by 21 days post-dose 1 for all adjuvanted groups, indicating that a single-dose vaccination strategy may be feasible for H9N2 vaccines.",
            "startOffset": 32588,
            "title": "Discussion"
        },
        {
            "endOffset": 23525,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Secondary objectives included evaluation of AS03 adjuvant effect on immunogenicity; assessment of CBER/CHMP criteria for the unadjuvanted formulation; hemagglutination inhibition (HI) antibody response up to day 546; microneutralization (MN) titers; and reactogenicity and safety.",
            "startOffset": 23245,
            "title": "Objectives"
        },
        {
            "endOffset": 24207,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The following parameters were derived from the HI assay: seropositivity rate, seroprotection rate (SPR), geometric mean titer (GMT), seroconversion rate (SCR), and mean geometric increase (MGI).",
            "startOffset": 24013,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32360,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "No pIMDs were reported.",
            "startOffset": 32337,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 31605,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Fever was rarely reported.",
            "startOffset": 31579,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 20141,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase I/II, observer-blind, randomized, placebo-controlled study was conducted in 3 centers in the United States (US) and 1 in Canada, between August 2012 and March 2014.",
            "startOffset": 19966,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32336,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "One participant experienced an SAE (schizophreniform disorder, onset day 22; control group) that led to withdrawal from the study.",
            "startOffset": 32206,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 25528,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "For MN GMT and VRR calculations, seronegative participants were assigned reciprocal titers of 14 (half the minimal reciprocal titer detectable).",
            "startOffset": 25384,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 27451,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Adjuvant benefit was demonstrated according to regulatory acceptance criterion of GMT ratio: if the LL of 95% CIs of HI GMT ratio of adjuvanted formulations over unadjuvanted formulation was >1.",
            "startOffset": 27257,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37151,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 37150,
                    "startOffset": 37146
                }
            },
            "secId": "s0075",
            "sentence": "We observed a trend towards higher GMT ratio (adjuvanted/unadjuvanted) for AS03A- compared to AS03B-adjuvanted formulations at 21 days post-dose 1 and 2, consistent with AS03 dose effect as observed previously [19].",
            "startOffset": 36936,
            "title": "Discussion"
        },
        {
            "endOffset": 34925,
            "parents": [],
            "secId": "s0075",
            "sentence": "The low level of cross-reactivity could be because ferret antiserum was elicited by a one-time infection, whereas adult humans have repeated exposure over decades to shared epitopes of HA globular head domain of diverse H1N1 viruses.",
            "startOffset": 34692,
            "title": "Discussion"
        },
        {
            "endOffset": 34132,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 34131,
                    "startOffset": 34128
                }
            },
            "secId": "s0075",
            "sentence": "Similar findings were reported by Atmar et al. when assessing seropositivity against the same H9N2 strain; moreover, they noted that the frequency of pre-vaccination seropositivity was much lower for G1 than G9 strains, in both younger and older adults [6].",
            "startOffset": 33875,
            "title": "Discussion"
        },
        {
            "endOffset": 24894,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "SCR was defined as proportion of participants with either reciprocal HI titer <10 pre-vaccination and \u226540 post-vaccination, or pre-vaccination reciprocal titer \u226510 and \u22654-fold increase post-vaccination; \u2018pre-vaccination\u2019 was day 0 for dose 1 and 2 assessments, and day 182 for dose 3 assessments.",
            "startOffset": 24598,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 29512,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Baseline antibody GMTs ranged between 8.7 and 14.2 for HI and between 49.3 and 61.4 for MN.",
            "startOffset": 29421,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35401,
            "parents": [],
            "secId": "s0075",
            "sentence": "G1 and Y280 lineages appear to differ in immunogenicity, although other factors may play a role, including differences in adjuvants or in assays used to measure the response.",
            "startOffset": 35227,
            "title": "Discussion"
        },
        {
            "endOffset": 35532,
            "parents": [],
            "secId": "s0075",
            "sentence": "We observed a rapid immune response to a single dose, even for unadjuvanted vaccine, with increased HI GMTs at 7 days post-dose 1.",
            "startOffset": 35402,
            "title": "Discussion"
        },
        {
            "endOffset": 38332,
            "parents": [],
            "secId": "s0075",
            "sentence": "Firstly, we enrolled only healthy adults; thus, effect of health status on immune responses was not evaluated.",
            "startOffset": 38222,
            "title": "Discussion"
        },
        {
            "endOffset": 37514,
            "parents": [],
            "secId": "s0075",
            "sentence": "This third dose led to a marked increase in HI GMTs, persisting to 12 months post-dose 3.",
            "startOffset": 37425,
            "title": "Discussion"
        },
        {
            "endOffset": 37424,
            "parents": [],
            "secId": "s0075",
            "sentence": "We assessed quality of priming by evaluating immune responses elicited by a third H9N2 vaccine dose administered 182 days post-dose 1.",
            "startOffset": 37290,
            "title": "Discussion"
        },
        {
            "endOffset": 38495,
            "parents": [],
            "secId": "s0075",
            "sentence": "Secondly, the study was not powered to draw statistically significant conclusions on differences between various formulations; these comparisons were descriptive.",
            "startOffset": 38333,
            "title": "Discussion"
        },
        {
            "endOffset": 28540,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The mean participant age was 42.3 years.",
            "startOffset": 28500,
            "title": "Population"
        },
        {
            "endOffset": 20723,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Periodic reviews of clinical safety data were performed by an internal Safety Review Committee.",
            "startOffset": 20628,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35774,
            "parents": [],
            "secId": "s0075",
            "sentence": "SPR reached 100% after 2 doses for all vaccinated groups in both age categories, including those receiving unadjuvanted vaccine.",
            "startOffset": 35646,
            "title": "Discussion"
        },
        {
            "endOffset": 28178,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "All CIs computed were two-sided 95% CIs.",
            "startOffset": 28138,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 22863,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Participants, those responsible for evaluation of study endpoints and the sponsor were unaware of treatment assignments.",
            "startOffset": 22743,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 32444,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "AESIs were reported for 2 participants of the control group (lip edema, urticaria).",
            "startOffset": 32361,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 39179,
            "parents": [],
            "secId": "s0075",
            "sentence": "In the event of an H9N2 pandemic, a single low-content dose of AS03-adjuvanted inactivated vaccine could contribute to an effective public health response.",
            "startOffset": 39024,
            "title": "Discussion"
        },
        {
            "endOffset": 39831,
            "parents": [],
            "secId": "s0085",
            "sentence": "ES and HC conducted several clinical trials with the GSK group of companies.",
            "startOffset": 39755,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 22220,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Vaccine groups received 2 doses (days 0, 21) of 1.9 \u00b5g HA + AS03 A, 1.9 \u00b5g HA + AS03B, 3.75 \u00b5g HA + AS03A, 3.75 \u00b5g HA + AS03B, or 15 \u03bcg HA unadjuvanted antigen, followed by a third dose of the same formulation (VVV groups) or saline placebo (VVP groups) on day 182.",
            "startOffset": 21955,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 29110,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "When comparing adjusted HI GMTs, adjuvant effect was demonstrated for all groups except 1.9B at day 21, and for all groups at day 42 (Table 2).",
            "startOffset": 28967,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37290,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 37289,
                    "startOffset": 37284
                },
                "b0030": {
                    "endOffset": 37289,
                    "startOffset": 37284
                }
            },
            "secId": "s0075",
            "sentence": "No clear impact of higher antigen content on immune response was observed for adjuvanted formulations, as reported in other studies [5,7].",
            "startOffset": 37152,
            "title": "Discussion"
        },
        {
            "endOffset": 31684,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "No increase in reactogenicity was observed post-dose 3 (Supplementary Fig. 1).",
            "startOffset": 31606,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 22266,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The control group received 3 doses of saline.",
            "startOffset": 22221,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 28860,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "To assess regulatory immunogenicity criteria and adjuvant effect, data from participants receiving the same priming regimen were pooled.",
            "startOffset": 28724,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31762,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Unsolicited AE incidences were similar for all groups (Supplementary Table 6).",
            "startOffset": 31684,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 19922,
            "parents": [],
            "secId": "s0005",
            "sentence": "We also assessed the quality of 2-dose priming by evaluating the immune response elicited by a third dose administered at day 182.",
            "startOffset": 19792,
            "title": "Introduction"
        },
        {
            "endOffset": 28138,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Humoral immune responses in terms of MN antibodies were assessed for a sub-cohort, randomly selected through the internet-based randomization system.",
            "startOffset": 27989,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33506,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 33505,
                    "startOffset": 33501
                }
            },
            "secId": "s0075",
            "sentence": "Cross-reactivity with pre-existing antibodies to H2N2 was proposed as an explanation for baseline H9N2 seropositivity [10].",
            "startOffset": 33383,
            "title": "Discussion"
        },
        {
            "endOffset": 26411,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "420 persons were to be enrolled.",
            "startOffset": 26379,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38182,
            "parents": [],
            "secId": "s0075",
            "sentence": "Although H9N2 vaccine was associated with higher reactogenicity than placebo, the vaccine had an acceptable safety profile, and most participants completed the 2-dose schedule and returned for dose 3.",
            "startOffset": 37982,
            "title": "Discussion"
        },
        {
            "endOffset": 37982,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 37796,
                    "startOffset": 37792
                },
                "b0100": {
                    "endOffset": 37838,
                    "startOffset": 37834
                }
            },
            "secId": "s0075",
            "sentence": "As higher HI antibody GMTs are associated with greater vaccine efficacy of seasonal [20] and H1N1 pandemic influenza vaccines [21], adjuvanted formulations may offer greater clinical benefit, although titers for the unadjuvanted formulation were also well above the cut-off.",
            "startOffset": 37708,
            "title": "Discussion"
        },
        {
            "endOffset": 33382,
            "parents": [],
            "secId": "s0075",
            "sentence": "H2N2 circulated widely from 1957 to 68, and correlation with reactivity to H9N2 in pre-vaccination samples was observed for H2 but not for H3N2, H1N1, or H3N7.",
            "startOffset": 33223,
            "title": "Discussion"
        },
        {
            "endOffset": 38819,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 38735,
                    "startOffset": 38727
                },
                "b0020": {
                    "endOffset": 38735,
                    "startOffset": 38727
                },
                "b0025": {
                    "endOffset": 38735,
                    "startOffset": 38727
                },
                "b0105": {
                    "endOffset": 38818,
                    "startOffset": 38811
                },
                "b0110": {
                    "endOffset": 38818,
                    "startOffset": 38811
                }
            },
            "secId": "s0075",
            "sentence": "Of note, previous studies have shown cross-protection between G1 and Y280 lineages to be poor [4\u20136,22], but have shown some cross-protection between clades within these lineages [22,23].",
            "startOffset": 38633,
            "title": "Discussion"
        },
        {
            "endOffset": 22569,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Treatment allocation at investigator sites was performed using an internet-based randomization system that used a minimization procedure accounting for center, age groups (18\u201340; 41\u201364 years), and receipt of influenza vaccine (seasonal and/or H1N1 pandemic) in the previous 3 influenza seasons (yes/no).",
            "startOffset": 22266,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 19129,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vaccine development against potential pandemic subtypes is a key strategy for pandemic preparedness.",
            "startOffset": 19029,
            "title": "Introduction"
        },
        {
            "endOffset": 18710,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 18709,
                    "startOffset": 18706
                }
            },
            "secId": "s0005",
            "sentence": "While H9N2 viruses have been mildly pathogenic avian influenza viruses with limited incidence and severity in humans [1].",
            "startOffset": 18589,
            "title": "Introduction"
        },
        {
            "endOffset": 21843,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Volumes administered per dose differed among formulations (1.9 \u00b5g HA + AS03A: 0.375 \u00b5L; 3.75 \u00b5g HA + AS03A, 3.75 \u00b5g HA + AS03B, and placebo: 0.5 mL; 1.9 \u00b5g HA + AS03B: 0.25 mL; 15 \u00b5g HA: 1 mL).",
            "startOffset": 21650,
            "title": "Study vaccine"
        },
        {
            "endOffset": 21649,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Vaccines or placebo were administered intramuscularly into the deltoid region.",
            "startOffset": 21571,
            "title": "Study vaccine"
        },
        {
            "endOffset": 18588,
            "parents": [],
            "secId": "s0005",
            "sentence": "Influenza pandemics occur when a novel influenza virus emerges and the majority of the human population has no immunity.",
            "startOffset": 18468,
            "title": "Introduction"
        },
        {
            "endOffset": 23245,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Co-primary objectives were to assess whether the adjuvanted formulations induced an immune response to vaccine-homologous virus that met US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) and European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) guidance targets, 21 days after the first and second dose.",
            "startOffset": 22876,
            "title": "Objectives"
        },
        {
            "endOffset": 30880,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Participants\u2019 influenza vaccination history in the last 3 years did not have a consistent impact on antibody levels (data not shown).",
            "startOffset": 30747,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37570,
            "parents": [],
            "secId": "s0075",
            "sentence": "Microneutralization GMTs also showed a robust increase.",
            "startOffset": 37515,
            "title": "Discussion"
        },
        {
            "endOffset": 38221,
            "parents": [],
            "secId": "s0075",
            "sentence": "This study had a number of limitations.",
            "startOffset": 38182,
            "title": "Discussion"
        },
        {
            "endOffset": 20462,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from each participant before study participation.",
            "startOffset": 20375,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29304,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Day 182 persistence results for the pooled groups are shown in Table 3.",
            "startOffset": 29233,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21570,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Placebo control was saline.",
            "startOffset": 21543,
            "title": "Study vaccine"
        },
        {
            "endOffset": 29420,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Pre-vaccination, 35.7%\u201344.8% of participants were seropositive for HI antibodies, and 79.2%\u201388.9% for MN antibodies.",
            "startOffset": 29304,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 26631,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Participants receiving the same priming regimen (e.g. 1.9A-VVV and 1.9A-VVP) were pooled for evaluation of the primary objective and for persistence at day 182, yielding approximately 60 participants per analysis group.",
            "startOffset": 26412,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 39867,
            "parents": [],
            "secId": "s0085",
            "sentence": "LF and LC have nothing to disclose.",
            "startOffset": 39832,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 26742,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Assuming 10% loss of participants from the per-protocol (PP) cohort gives 54 evaluable participants per group.",
            "startOffset": 26632,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 27052,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 26849,
                    "startOffset": 26845
                }
            },
            "secId": "s0050",
            "sentence": "Assuming H9N2 being at least as immunogenic as GSK\u2019s AS03-adjuvanted H5N1 vaccine (SCR = SPR = 90.8%) [13], our sample size allowed at least 97.6% power to fulfill CBER and CHMP criteria in any one of the four adjuvanted vaccine groups, and 90.4% global power to fulfill CBER/CHMP criteria in all four groups.",
            "startOffset": 26743,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 19604,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 19603,
                    "startOffset": 19599
                }
            },
            "secId": "s0005",
            "sentence": "However, as manufacturing facilities may be overwhelmed by demand during a pandemic, antigen-sparing through adjuvantation becomes an important strategy for faster and broader pandemic vaccination response [12].",
            "startOffset": 19393,
            "title": "Introduction"
        },
        {
            "endOffset": 39754,
            "parents": [],
            "secId": "s0085",
            "sentence": "AM, DM, DWV, BLI and AS own stock/stock options/restricted shares of the GSK group of companies.",
            "startOffset": 39658,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 36279,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 36278,
                    "startOffset": 36274
                }
            },
            "secId": "s0075",
            "sentence": "However, another study found poor antibody responses to unadjuvanted G1 H9N2 vaccine in participants younger than 32 years, fulfilling none of the immunogenicity criteria after 1 dose; moreover, limited to no increase in immunogenicity from dose 1 to dose 2 was observed for subunit vaccine in both age groups [10].",
            "startOffset": 35964,
            "title": "Discussion"
        },
        {
            "endOffset": 40187,
            "parents": [],
            "secId": "s0090",
            "sentence": "GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis.",
            "startOffset": 40095,
            "title": "Funding statement"
        },
        {
            "endOffset": 30149,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Participants who received a third vaccine dose at day 182 after a 2-dose primary series, showed an anamnestic response with a robust increase in HI and MN GMTs 9 days post-dose 3 (day 191) (Fig. 2B, Supplementary Tables 2 and 4).",
            "startOffset": 29920,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40485,
            "parents": [],
            "secId": "s0095",
            "sentence": "Partial data were presented as an abstract and poster at Options for the Control of Influenza VIII Conference (September 2013, Cape Town, South Africa).",
            "startOffset": 40333,
            "title": "Previous presentations"
        },
        {
            "endOffset": 23637,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Venous blood samples were collected on days 0, 7, 21, 28, 42, 182, 191, 385 and 546.",
            "startOffset": 23553,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 21415,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The inactivated split-virus vaccine formulations (GSK Vaccines, Quebec, Canada) contained 1.9 or 3.75 \u00b5g HA of A/chicken/Hong Kong/G9/1997 NIBRG-91 virus strain adjuvanted with AS03A or AS03B, or 15 \u00b5g unadjuvanted HA.",
            "startOffset": 21197,
            "title": "Study vaccine"
        },
        {
            "endOffset": 27988,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Immunogenicity analyses were based on PP cohorts (at day 21, 42, 182, 191, 385, or 546), including all evaluable participants (meeting all eligibility criteria, complying with study protocol), who had received the relevant study doses (1 dose for day 21 PP cohort, 2 doses for days 42 and 182, and 3 doses for days 191, 385 and 546), and had assay results available for blood sample(s) taken during the analysis interval.",
            "startOffset": 27567,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38632,
            "parents": [],
            "secId": "s0075",
            "sentence": "Lastly, we did not examine whether the vaccine provided any cross-protection against other H9N2 lineages (e.g. G1) or other Y280 clades.",
            "startOffset": 38496,
            "title": "Discussion"
        },
        {
            "endOffset": 40094,
            "parents": [],
            "secId": "s0090",
            "sentence": "The trial was funded by the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (HHS/BARDA; HHSO100200700029C) and GlaxoSmithKline Biologicals SA.",
            "startOffset": 39884,
            "title": "Funding statement"
        },
        {
            "endOffset": 26081,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Reports of AEs of specific interest (AESIs) were identified using MedDRA preferred terms or standardized MedDRA queries as recommended by CHMP.",
            "startOffset": 25938,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 19791,
            "parents": [],
            "secId": "s0005",
            "sentence": "We evaluated different regimens of monovalent split-virus Y280-like influenza A/chicken/Hong Kong/G9/1997 (H9N2) vaccine with or without adjuvant system AS03 in adults 18\u201364 years of age.",
            "startOffset": 19604,
            "title": "Introduction"
        },
        {
            "endOffset": 29232,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "There was a trend towards higher MGI for AS03A compared to AS03B, while antigen content did not have an impact (Table 2).",
            "startOffset": 29111,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31017,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Injection site pain was reported more frequently in adjuvanted than unadjuvanted or placebo groups (Fig. 3A).",
            "startOffset": 30908,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28500,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "420 individuals received study vaccine or placebo (Fig. 1); 397 completed the day 182 visit, 370 continued the persistence phase until day 385, and 365 until day 546.",
            "startOffset": 28334,
            "title": "Population"
        },
        {
            "endOffset": 22742,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The study was conducted in an observer-blind manner; vaccine and placebo preparation and administration were done by personnel not participating in any clinical evaluations.",
            "startOffset": 22569,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 32587,
            "parents": [],
            "secId": "s0075",
            "sentence": "In healthy adults 18\u201364 years of age, 2 doses of AS03A- or AS03B-adjuvanted H9N2 candidate vaccine elicited robust immune responses.",
            "startOffset": 32455,
            "title": "Discussion"
        },
        {
            "endOffset": 39425,
            "parents": [],
            "secId": "s0080",
            "sentence": "All authors had full access to the data and gave final approval before submission.",
            "startOffset": 39343,
            "title": "Authors contribution"
        },
        {
            "endOffset": 39023,
            "parents": [],
            "secId": "s0075",
            "sentence": "An anamnestic immune response was observed after a third dose administered 182 days post-dose 1.",
            "startOffset": 38927,
            "title": "Discussion"
        },
        {
            "endOffset": 25937,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Medically-attended AEs (MAEs), potential immune-mediated diseases (pIMDs), and serious AEs (SAEs) were collected throughout the study.",
            "startOffset": 25803,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 38926,
            "parents": [],
            "secId": "s0075",
            "sentence": "In conclusion, all H9N2 vaccine formulations were immunogenic, with a clinically acceptable safety profile.",
            "startOffset": 38819,
            "title": "Discussion"
        },
        {
            "endOffset": 19029,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 19028,
                    "startOffset": 19025
                }
            },
            "secId": "s0005",
            "sentence": "However, H9N2 viruses have the potential to evolve into highly pathogenic pandemic viruses [3].",
            "startOffset": 18934,
            "title": "Introduction"
        },
        {
            "endOffset": 32205,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "SAEs were reported by 18 participants (Supplementary Table 6); none were considered by the investigator or sponsor to be related to vaccination, and none were fatal.",
            "startOffset": 32040,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24316,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Participants were considered seropositive if they had an antibody titer above or equal to the assay cut-off.",
            "startOffset": 24208,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 31333,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The most commonly reported solicited general symptoms were fatigue, headache and muscle ache.",
            "startOffset": 31240,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33222,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 33221,
                    "startOffset": 33217
                }
            },
            "secId": "s0075",
            "sentence": "In another study, 24/60 pre-vaccination samples had reactivity to a G1 H9N2 strain; all were from participants born before 1969 [10].",
            "startOffset": 33089,
            "title": "Discussion"
        },
        {
            "endOffset": 37707,
            "parents": [],
            "secId": "s0075",
            "sentence": "While the unadjuvanted preparation was able to boost the immune response, GMTs remained markedly lower than for adjuvanted formulations.",
            "startOffset": 37571,
            "title": "Discussion"
        },
        {
            "endOffset": 36936,
            "parents": [],
            "secId": "s0075",
            "sentence": "Our adjuvanted formulations permit an 8-fold antigen dose reduction (1.9 vs 15 \u00b5g) while improving humoral immune response, which would allow increased access to vaccination during a pandemic response.",
            "startOffset": 36735,
            "title": "Discussion"
        },
        {
            "endOffset": 30252,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Thereafter, HI GMTs for these participants remained high to 12 months post-dose 3 (day 546) (Fig. 2B).",
            "startOffset": 30150,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 36659,
            "parents": [],
            "secId": "s0075",
            "sentence": "Although unadjuvanted vaccine met immunogenicity criteria, antibody titers increased only slightly post-dose 2, remaining much lower than following adjuvanted vaccination for all time points to day 182.",
            "startOffset": 36457,
            "title": "Discussion"
        },
        {
            "endOffset": 39501,
            "parents": [],
            "secId": "s0080",
            "sentence": "The corresponding author was responsible for submission of the publication.",
            "startOffset": 39426,
            "title": "Authors contribution"
        },
        {
            "endOffset": 21542,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "AS03 is an adjuvant system containing \u03b1-tocopherol (AS03A: 11.86 mg; AS03B: 5.93 mg) and squalene in an oil-in-water emulsion.",
            "startOffset": 21416,
            "title": "Study vaccine"
        },
        {
            "endOffset": 40531,
            "parents": [],
            "secId": "s0095",
            "sentence": "This manuscript discloses more complete data.",
            "startOffset": 40486,
            "title": "Previous presentations"
        },
        {
            "endOffset": 29617,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Strong increases in HI GMTs were observed both at 7 and 21 days after each vaccine dose (Fig. 2A and B).",
            "startOffset": 29513,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 28966,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "At days 21 and 42, all vaccine recipient groups exceeded CBER and CHMP immunogenicity criteria (Table 2).",
            "startOffset": 28861,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31120,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Grade 3 injection site pain was reported by 1 participant post-dose 1, and 6 participants post-dose 2.",
            "startOffset": 31018,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 25802,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Grade 3 unsolicited AEs were those preventing normal, everyday activities.",
            "startOffset": 25728,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 19392,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 19391,
                    "startOffset": 19385
                },
                "b0025": {
                    "endOffset": 19391,
                    "startOffset": 19385
                },
                "b0030": {
                    "endOffset": 19391,
                    "startOffset": 19385
                },
                "b0035": {
                    "endOffset": 19391,
                    "startOffset": 19385
                },
                "b0040": {
                    "endOffset": 19391,
                    "startOffset": 19385
                },
                "b0045": {
                    "endOffset": 19391,
                    "startOffset": 19385
                },
                "b0050": {
                    "endOffset": 19391,
                    "startOffset": 19385
                }
            },
            "secId": "s0005",
            "sentence": "Several H9N2 candidate vaccines have been developed [5\u201311].",
            "startOffset": 19333,
            "title": "Introduction"
        },
        {
            "endOffset": 25383,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "For the MN assay, derived parameters were seropositivity rate, GMT, and vaccine response rate (VRR; proportion of vaccinees with post-vaccination reciprocal titer \u22654-fold higher than pre-vaccination, with \u2018pre-vaccination\u2019 being day 0 for dose 1 and 2 assessments, and day 182 for dose 3 assessments).",
            "startOffset": 25082,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 30469,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 30395,
                    "startOffset": 30391
                }
            },
            "secId": "s0065",
            "sentence": "Because data suggested that some persons born before 1969 may have been primed by exposure to H2N2 viruses to react anamnestically to H9N2 [10], we performed a sub-analysis by age strata (18\u201340 years and 41\u201364 years).",
            "startOffset": 30252,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 39342,
            "parents": [],
            "secId": "s0080",
            "sentence": "All authors participated in the design, implementation or analysis, or the interpretation of the study, and the development of this manuscript.",
            "startOffset": 39199,
            "title": "Authors contribution"
        },
        {
            "endOffset": 32952,
            "parents": [],
            "secId": "s0075",
            "sentence": "This is the first demonstration of robust immunogenicity of AS03-adjuvanted H9N2 vaccine formulations, which were highly dose-sparing and had a clinically acceptable safety profile.",
            "startOffset": 32771,
            "title": "Discussion"
        },
        {
            "endOffset": 35963,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 35858,
                    "startOffset": 35855
                },
                "b0025": {
                    "endOffset": 35962,
                    "startOffset": 35959
                }
            },
            "secId": "s0075",
            "sentence": "Similarly, MF59-adjuvanted G9 H9N2 preparations were immunogenic after one dose [5], and vaccinees born before 1968 were not more likely to respond to vaccination than younger persons [6].",
            "startOffset": 35775,
            "title": "Discussion"
        },
        {
            "endOffset": 36734,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 36733,
                    "startOffset": 36729
                }
            },
            "secId": "s0075",
            "sentence": "Similar findings were reported for another unadjuvanted H9N2 vaccine [10].",
            "startOffset": 36660,
            "title": "Discussion"
        },
        {
            "endOffset": 19332,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 19331,
                    "startOffset": 19328
                }
            },
            "secId": "s0005",
            "sentence": "Multiple clades of H9N2 viruses have been identified, most of which belong to either the G1-like lineage (e.g. A/quail/Hong Kong/G1/1997) or the Y280-like lineage (e.g. A/chicken/Hong Kong/G9/1997) [4].",
            "startOffset": 19130,
            "title": "Introduction"
        },
        {
            "endOffset": 35141,
            "parents": [],
            "secId": "s0075",
            "sentence": "Cross-reactivity with H1N1 is further supported by HI assays on serum samples of H1N1 vaccinees; 25/40 samples were positive for H9N2 (2/10 pre-vaccination, 5/11 post-dose 1 and 18/19 post-dose 2; unpublished data).",
            "startOffset": 34926,
            "title": "Discussion"
        },
        {
            "endOffset": 35645,
            "parents": [],
            "secId": "s0075",
            "sentence": "This corresponds to an anamnestic response, and could be explained by the high level of baseline seropositivity.",
            "startOffset": 35533,
            "title": "Discussion"
        },
        {
            "endOffset": 20266,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with Good Clinical Practice guidelines, Declaration of Helsinki and local regulations.",
            "startOffset": 20142,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35227,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 35226,
                    "startOffset": 35222
                }
            },
            "secId": "s0075",
            "sentence": "Besides HA, cross-reactivity between the N2 of H9N2 and H3N2 has been discussed [18].",
            "startOffset": 35142,
            "title": "Discussion"
        },
        {
            "endOffset": 21954,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Participants were randomized to 1 of 10 vaccine groups or control group (Table 1).",
            "startOffset": 21872,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 31578,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "General symptoms tended to be less frequent in the placebo group; incidences for unadjuvanted and adjuvanted groups were generally in the same range, except for muscle ache which was reported less frequently in the unadjuvanted group (Fig. 3B).",
            "startOffset": 31334,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28313,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Statistical analyses were performed using Statistical Analysis Systems (SAS) version 9.2 on Windows and StatXact-8.1 procedure on SAS.",
            "startOffset": 28179,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 27566,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Safety analyses were based on the total vaccinated cohort, including all participants who received at least 1 dose.",
            "startOffset": 27451,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30525,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Age did not affect SPRs and SCRs in the vaccine groups.",
            "startOffset": 30470,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21181,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Women of childbearing potential had to practice adequate contraception from 30 days pre-vaccination to 2 months post-dose 3, and have a negative pregnancy test on the days of vaccination.",
            "startOffset": 20994,
            "title": "Eligibility criteria"
        },
        {
            "endOffset": 27256,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "CBER criteria were met if the lower limit (LL) of the 95% confidence interval (CI) was \u226540% for SCR and \u226570% for SPR, and CHMP criteria if point estimates were >40% for SCR, >70% for SPR and >2.5 for MGI.",
            "startOffset": 27052,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 32040,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Grade 3 unsolicited AEs considered causally related to vaccination were reported for 1 participant post-dose 1 (3.75B group; pain in right leg and paresthesia in both arms and right leg, resolved in 9 days) and post-dose 3 (pharyngitis; 15-VVP group), and for none post-dose 2.",
            "startOffset": 31763,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 39657,
            "parents": [],
            "secId": "s0085",
            "sentence": "BLI was an employee of the GSK group of companies during the study.",
            "startOffset": 39590,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 24411,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "SPR was defined as proportion of participants with reciprocal HI titers \u2265 40 post-vaccination.",
            "startOffset": 24317,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 31239,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Incidences of injection site redness and swelling were low, and no grade 3 redness or swelling was reported (Fig. 3A).",
            "startOffset": 31121,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 34495,
            "parents": [],
            "secId": "s0075",
            "sentence": "The baseline H9N2 seropositivity in younger participants suggests that prior exposures to seasonal influenza A group 1 viruses other than H9 may have elicited antibodies that are cross-reactive with vaccine virus H9 head domain.",
            "startOffset": 34267,
            "title": "Discussion"
        },
        {
            "endOffset": 20533,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The study has been registered at www.clinicaltrials.gov (NCT01659086).",
            "startOffset": 20463,
            "title": "Study design and participants"
        },
        {
            "endOffset": 28707,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Age and gender distributions were generally similar among groups, with a slightly higher proportion of females in the placebo and 1.9B groups (Supplementary Table 1).",
            "startOffset": 28541,
            "title": "Population"
        },
        {
            "endOffset": 33088,
            "parents": [],
            "secId": "s0075",
            "sentence": "Despite our study population being supposedly na\u00efve to H9, baseline HI antibody seropositivity ranged from 35.7% to 44.8% across groups.",
            "startOffset": 32952,
            "title": "Discussion"
        },
        {
            "endOffset": 40311,
            "parents": [],
            "secId": "s0090",
            "sentence": "GlaxoSmithKline Biologicals SA paid for costs associated with the development and the publishing of the present manuscript.",
            "startOffset": 40188,
            "title": "Funding statement"
        },
        {
            "endOffset": 25727,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Diary cards were used to record solicited injection site and general symptoms within 7 days, and unsolicited adverse events (AEs) within 21 days post-each dose.",
            "startOffset": 25567,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 29817,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "For participants who received placebo at day 182, HI GMTs peaked at day 42 and decreased over time thereafter, though GMTs remained well above baseline up to day 546 (Fig. 2A, Supplementary Table 2).",
            "startOffset": 29618,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30747,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "HI GMTs were generally not affected by age, except in the 1.9B group where GMTs in the 41\u201364 years age stratum were generally half of those in the 18\u201340 years stratum, but with overlapping 95% CIs (Supplementary Table 5).",
            "startOffset": 30526,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 24013,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Immunogenicity against A/chicken/Hong Kong/G9/1997 (H9N2)-like influenza virus was assessed for each of these time points using an HI assay and for days 0, 21, 42, 182 and 191 using a MN assay (further details can be found in the online supplement), performed by Viroclinics Biosciences B.V. Assay cut-offs were 10 for HI and 28 for MN (reciprocal of initial serum dilution).",
            "startOffset": 23638,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 18933,
            "parents": [],
            "refoffsets": {
                "b9005": {
                    "endOffset": 18932,
                    "startOffset": 18929
                }
            },
            "secId": "s0005",
            "sentence": "For example, there was one human H9N2 influenza case reported in 2016, in a 7-month-old girl in China, who developed mild disease after visiting a live poultry market and recovered without the need for hospitalization [2].",
            "startOffset": 18711,
            "title": "Introduction"
        },
        {
            "endOffset": 33683,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 33682,
                    "startOffset": 33677
                },
                "b0035": {
                    "endOffset": 33682,
                    "startOffset": 33677
                }
            },
            "secId": "s0075",
            "sentence": "However, 2 studies with A/chicken/Hong Kong/G9/97 (H9N2) strains enrolled only persons born after 1969 but still observed baseline seropositivity in \u223c30% of participants [5,8].",
            "startOffset": 33507,
            "title": "Discussion"
        },
        {
            "endOffset": 36457,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 36456,
                    "startOffset": 36453
                }
            },
            "secId": "s0075",
            "sentence": "For aluminum-adjuvanted whole-virus formulations and unadjuvanted split-virus vaccine based on a G1-like H9N2 strain, CHMP criteria were met post-dose 2 but not post-dose 1 [7].",
            "startOffset": 36280,
            "title": "Discussion"
        },
        {
            "endOffset": 25082,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "MGI was defined as geometric mean of within-subject ratios of post-vaccination to pre-vaccination (day 0) reciprocal HI titer for dose 1 and 2, or post- to pre-dose 3 reciprocal HI titer.",
            "startOffset": 24895,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 20993,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Healthy persons 18\u201364 years of age (inclusive) at the time of first study vaccination, weighing \u226549.9 kg, were enrolled if the investigator determined that they would comply with the study protocol (detailed exclusion criteria: online supplement).",
            "startOffset": 20746,
            "title": "Eligibility criteria"
        },
        {
            "endOffset": 29920,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "MN GMTs also peaked at day 42, and were well above baseline at day 191 (Supplementary Tables 3 and 4).",
            "startOffset": 29818,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33874,
            "parents": [],
            "secId": "s0075",
            "sentence": "In our study, participants from both the 18\u201340 years (born after 1969) and 41\u201364 years category were seropositive at baseline, although a higher proportion was seen in the older age stratum.",
            "startOffset": 33684,
            "title": "Discussion"
        },
        {
            "endOffset": 34691,
            "parents": [],
            "secId": "s0075",
            "sentence": "Assay specificity was determined using antigen\u2010specific ferret sera, assayed against homologous and unrelated influenza strains; low cross\u2010reactivity was observed with H1N1pdm09 (data not shown).",
            "startOffset": 34496,
            "title": "Discussion"
        },
        {
            "endOffset": 34266,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 34238,
                    "startOffset": 34231
                },
                "b0070": {
                    "endOffset": 34238,
                    "startOffset": 34231
                },
                "b0075": {
                    "endOffset": 34265,
                    "startOffset": 34258
                },
                "b0080": {
                    "endOffset": 34265,
                    "startOffset": 34258
                }
            },
            "secId": "s0075",
            "sentence": "Phylogenetically, influenza type A viruses are classified into different HA subtypes (currently 18 [14,15]), forming 2 groups [16,17].",
            "startOffset": 34132,
            "title": "Discussion"
        },
        {
            "endOffset": 26356,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "SAEs were any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, or was a congenital anomaly or birth defect in a study participant\u2019s offspring.",
            "startOffset": 26081,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 20374,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "All study-related documents were approved by an independent ethics committee or institutional review board.",
            "startOffset": 20267,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24597,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "GMTs were calculated by taking the anti-log of the mean of the log (base 10) transformed reciprocal titers; titers below assay cut-off were given an arbitrary value of half the cut-off.",
            "startOffset": 24412,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 39589,
            "parents": [],
            "secId": "s0085",
            "sentence": "AM, DF, MD, DWV, and AS are employees of the GSK group of companies.",
            "startOffset": 39521,
            "title": "Conflict of interest"
        }
    ],
    "docId": "S0264410X1730909X",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Anu.2.Madan@gsk.com",
                "first": "Anuradha",
                "initial": "A.",
                "last": "Madan"
            },
            {
                "email": null,
                "first": "Harry",
                "initial": "H.",
                "last": "Collins"
            },
            {
                "email": null,
                "first": "Eric",
                "initial": "E.",
                "last": "Sheldon"
            },
            {
                "email": null,
                "first": "Louise",
                "initial": "L.",
                "last": "Frenette"
            },
            {
                "email": null,
                "first": "Laurence",
                "initial": "L.",
                "last": "Chu"
            },
            {
                "email": null,
                "first": "Damien",
                "initial": "D.",
                "last": "Friel"
            },
            {
                "email": null,
                "first": "Mamadou",
                "initial": "M.",
                "last": "Drame"
            },
            {
                "email": null,
                "first": "David W.",
                "initial": "D.W.",
                "last": "Vaughn"
            },
            {
                "email": null,
                "first": "Bruce L.",
                "initial": "B.L.",
                "last": "Innis"
            },
            {
                "email": null,
                "first": "Anne",
                "initial": "A.",
                "last": "Schuind"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.07.013",
        "firstpage": "4621",
        "issn": "0264410X",
        "keywords": [
            "Adjuvant system",
            "Anamnestic immune response",
            "H9N2",
            "Influenza",
            "Pandemic",
            "Vaccine"
        ],
        "lastpage": "4628",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial"
    }
}